First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Informations projet

PrasinoMed

N° de convention de subvention: 827272

DOI

10.3030/827272

Projet clôturé

Date de signature de la CE 9 Août 2018

Date de début 1 Août 2018

Date de fin 30 Novembre 2018

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

PRASINOTECH LTD
United Kingdom

Periodic Reporting for period 1 - PrasinoMed (First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus)

Période du rapport: 2018-08-01 au 2018-11-30

Résumé du contexte et des objectifs généraux du projet

PrasinoTech developed PrasinoSpray, a natural, cost-effective antiviral nasal spray suitable for cold prevention, sustainably manufactured from microalgae. It may also be beneficial for rhinitis suffer
nbavinch ers due to PrasinoMed’s anti-inflammatory properties. The overall objectives of the project are to finalise the formulation and complete a clinical trial to ensure the product is ready for commercial use.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Using SME Instrument Phase 1 funding, the company carried out a Feasibility Study from August 2018 until November 2018. The study explored both the technical and commercial feasibility of a nasal spray, using microalgae Prasinococcus capsulatus. Throughout the project, the company greatly expanded its knowledge of the business model, requirements for clinical validation and regulatory approval for European market launch.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Although mortality/morbidity is rare, common colds are responsible for considerable discomfort, absenteeism from school and work, and healthcare costs. The completion of the proposed project will result in a commercial-ready antiviral nasal spray suitable for cold prevention. The polysaccharide elicits effective and superior anti-viral and anti-inflammatory activity compared to other agents. In addition, PrasinoSpray is 100% natural, avoiding adverse effects of chemical compounds

1